CELF1 and myotonic dystrophy type 1: Using GSK3 inhibitors, we previously showed that the correction of the GSK3β-CUGBP1 pathway reduces the muscle phenotype in HSALR mice [20], a model for adult, classic DM1 expressing CUG repeats in skeletal muscle [24].